Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 7, 2017

Primary Completion Date

February 10, 2021

Study Completion Date

September 30, 2026

Conditions
Esophageal Adenocarcinoma
Interventions
DRUG

Pembrolizumab

Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

DRUG

Taxol

Taxol is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions.

DRUG

Carboplatin

Carboplatin is a platinum coordination compound that is used as a cancer chemotherapeutic agent. Carboplatin produces predominantly interstrand DNA cross-links rather than DNA -protein cross-links.

Trial Locations (4)

10068

Weill Cornell Medicine, New York

90033

USC Keck School of Medicine, Norris Cancer Center, Los Angeles

48109-5848

University of Michigan, Ann Arbor

02903

Rhode Island Hospital, Providence

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER